X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8) 8
double-blind method (7) 7
venous thromboembolism (7) 7
index medicus (6) 6
warfarin (6) 6
anticoagulants - adverse effects (5) 5
edoxaban (5) 5
hematology (5) 5
male (5) 5
anticoagulants (4) 4
cancer (4) 4
hemorrhage - chemically induced (4) 4
middle aged (4) 4
peripheral vascular disease (4) 4
pyridines - adverse effects (4) 4
thiazoles - adverse effects (4) 4
thrombosis (4) 4
venous thromboembolism - drug therapy (4) 4
abridged index medicus (3) 3
administration, oral (3) 3
adult (3) 3
aged (3) 3
anticoagulant drugs (3) 3
anticoagulants - administration & dosage (3) 3
anticoagulants - therapeutic use (3) 3
clinical trial (3) 3
dabigatran (3) 3
drug administration schedule (3) 3
drug therapy (3) 3
female (3) 3
kaplan-meier estimate (3) 3
medicine, general & internal (3) 3
prophylaxis (3) 3
pulmonary embolism (3) 3
pyridines - administration & dosage (3) 3
rivaroxaban (3) 3
secondary prevention (3) 3
stroke, systemic or venous thromboembolism (3) 3
thiazoles - administration & dosage (3) 3
thromboembolism (3) 3
active cancer (2) 2
atrial-fibrillation (2) 2
bleeding (2) 2
bleeding complications (2) 2
body weight (2) 2
clinical trials (2) 2
dalteparin - adverse effects (2) 2
dalteparin - therapeutic use (2) 2
double-blind (2) 2
embolisms (2) 2
enoxaparin (2) 2
events (2) 2
factor xa inhibitor (2) 2
factor xa inhibitors - administration & dosage (2) 2
factor xa inhibitors - adverse effects (2) 2
hemorrhage (2) 2
heparin (2) 2
life sciences (2) 2
management (2) 2
molecular-weight heparin (2) 2
neoplasms - complications (2) 2
oral rivaroxaban (2) 2
prevention (2) 2
prospective studies (2) 2
pulmonary embolism - drug therapy (2) 2
pyridines - therapeutic use (2) 2
recurrence (2) 2
research design (2) 2
thiazoles - therapeutic use (2) 2
time factors (2) 2
treatment outcome (2) 2
veins & arteries (2) 2
warfarin - administration & dosage (2) 2
warfarin - adverse effects (2) 2
[ sdv ] life sciences [q-bio] (1) 1
[sdv]life sciences [q-bio] (1) 1
a-cholesterol acyltransferase (1) 1
acute pulmonary-embolism (1) 1
acyl-coa (1) 1
angiography (1) 1
angiotensin receptor antagonists (1) 1
antagonist (1) 1
anticoagulant treatment (1) 1
anticoagulants, edoxaban (1) 1
area under curve (1) 1
arteries (1) 1
atherosclerosis (1) 1
avasimibe (1) 1
biological availability (1) 1
biomarkers - blood (1) 1
blood coagulation - drug effects (1) 1
blood coagulation tests (1) 1
blood-pressure (1) 1
brain natriuretic peptide (1) 1
cancer therapies (1) 1
cardiovascular agents (1) 1
cardiovascular disease (1) 1
care and treatment (1) 1
carotid artery diseases - blood (1) 1
carotid artery diseases - diagnostic imaging (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 15, pp. 1406 - 1415
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2018, Volume 378, Issue 7, pp. 615 - 624
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 2015, Volume 114, Issue 6, pp. 1268 - 1276
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 2018, Volume 118, Issue 8, pp. 1439 - 1449
In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding... 
Stroke, Systemic or Venous Thromboembolism | direct oral anticoagulants | cancer | anticoagulant treatment | major bleeding | venous thromboembolism | THERAPY | RIVAROXABAN | EDOXABAN | PATTERNS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY
Journal Article
Thrombosis and haemostasis, ISSN 0340-6245, 2016, Volume 116, Issue 1, pp. 155 - 161
Edoxaban is a once-daily direct oral anticoagulant (DOAC). The Hokusai-VTE study revealed that, after initial treatment with heparin, edoxaban was non-inferior... 
Stroke, Systemic or Venous Thromboembolism | Coumarins | Anticoagulants | Edoxaban | Haemorrhage | Venous thromboembolism | RISK-FACTORS | coumarins | RIVAROXABAN | haemorrhage | edoxaban | CHALLENGES | DABIGATRAN | WARFARIN | venous thromboembolism | ORAL ANTICOAGULANTS | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY
Journal Article
World journal of radiology, ISSN 1949-8470, 10/2018, Volume 10, Issue 10, pp. 124 - 134
To evaluate reproducibility of pulmonary embolism (PE) clot volume quantification using computed tomography pulmonary angiogram (CTPA) in a multicenter... 
Pulmonary embolism | Computed tomography angiography | Computer-assisted image analysis | Arteries | Observational Study | Thrombolytic therapy
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 15, pp. 1406 - 1415
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 2015, Volume 113, Issue 6, pp. 1268 - 1276
Summary Direct oral anticoagulants may be effective and safe for treatment of venous thromboembolism (VTE) in cancer patients, but they have not been compared... 
Stroke, Systemic or Venous Thromboembolism
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 2013, Volume 369, Issue 15, pp. 1406 - 15
BACKGROUND: Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS: In a... 
Anticoagulants | Warfarin | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Enoxaparin | Male | Hemorrhage | Venous Thromboembolism | Female | Aged | Pulmonary Embolism
Journal Article
JAMA, The Journal of the American Medical Association, ISSN 0098-7484, 03/2009, Volume 301, Issue 11, p. 1131
The study evaluates the efficacy of the inhibition of the intracellular enzyme acyle coenzyme, A:cholesterol acyltransferase (ACAT), with pactimibe in the... 
Prevention | Evaluation | Care and treatment | Hypercholesterolemia | Atherosclerosis | Drug therapy | Cardiovascular agents
Journal Article
Journal of Hypertension, ISSN 0263-6352, 06/2001, Volume 19 Suplement 1, pp. S33 - S33
In elderly (65–75 years old), after 80 mg olmesartan medoxomil once daily, and very elderly (≥ 75 years old) hypertensive patients after 10 mg daily,... 
Journal Article
Thrombosis and haemostasis, 08/2018, Volume 118, Issue 8, p. 1439
In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE) and major bleeding... 
Journal Article
Journal of thrombosis and haemostasis, ISSN 1538-7933, 2013, Volume 11, Issue 7, pp. 1287 - 1294
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.